Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.
MER Indicator |
MER description |
Target Fiscal Year |
Target |
HTS_TST |
25-29, Female, Negative |
2019 |
1,548 |
HTS_TST |
25-29, Female, Negative |
2019 |
996 |
HTS_TST |
25-29, Female, Negative |
2019 |
6 |
HTS_TST |
25-29, Female, Negative |
2019 |
206 |
HTS_TST |
25-29, Male, Negative |
2019 |
4,644 |
HTS_TST |
25-29, Male, Negative |
2019 |
26 |
HTS_TST |
25-29, Male, Negative |
2019 |
620 |
HTS_TST |
30-34, Female, Negative |
2019 |
1,548 |
HTS_TST |
30-34, Female, Negative |
2019 |
664 |
HTS_TST |
30-34, Female, Negative |
2019 |
7 |
HTS_TST |
30-34, Female, Negative |
2019 |
206 |
HTS_TST |
30-34, Male, Negative |
2019 |
4,644 |
HTS_TST |
30-34, Male, Negative |
2019 |
27 |
HTS_TST |
30-34, Male, Negative |
2019 |
620 |
HTS_TST |
35-39, Female, Negative |
2019 |
2,167 |
HTS_TST |
35-39, Female, Negative |
2019 |
15 |
HTS_TST |
35-39, Female, Negative |
2019 |
289 |
HTS_TST |
35-39, Male, Negative |
2019 |
6,500 |
HTS_TST |
35-39, Male, Negative |
2019 |
60 |
HTS_TST |
35-39, Male, Negative |
2019 |
867 |
HTS_TST |
40-49, Female, Negative |
2019 |
929 |
HTS_TST |
40-49, Female, Negative |
2019 |
4 |
HTS_TST |
40-49, Female, Negative |
2019 |
124 |
HTS_TST |
40-49, Male, Negative |
2019 |
2,787 |
HTS_TST |
40-49, Male, Negative |
2019 |
19 |
HTS_TST |
40-49, Male, Negative |
2019 |
371 |
HTS_TST |
Number of individuals who received T&C services for HIV and received their test results during the past 12 months |
2019 |
30,000 |
HTS_TST_POS |
30-34, Female, Positive |
2019 |
10 |
HTS_TST_POS |
30-34, Female, Positive |
2019 |
1 |
HTS_TST_POS |
30-34, Female, Positive |
2019 |
2 |
HTS_TST_POS |
30-34, Male, Positive |
2019 |
21 |
HTS_TST_POS |
30-34, Male, Positive |
2019 |
2 |
HTS_TST_POS |
30-34, Male, Positive |
2019 |
8 |
HTS_TST_POS |
35-39, Female, Positive |
2019 |
15 |
HTS_TST_POS |
35-39, Female, Positive |
2019 |
1 |
HTS_TST_POS |
35-39, Female, Positive |
2019 |
3 |
HTS_TST_POS |
35-39, Male, Positive |
2019 |
30 |
HTS_TST_POS |
35-39, Male, Positive |
2019 |
4 |
HTS_TST_POS |
35-39, Male, Positive |
2019 |
9 |
PP_PREV |
Age/sex: 20-24 Male |
2019 |
50,000 |
PP_PREV |
Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period |
2019 |
50,000 |
PP_PREV |
Sum of Age/Sex disaggregates |
2019 |
50,000 |
TB_STAT |
Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) |
2019 |
34 |
TB_STAT |
Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) |
2019 |
138 |
TB_STAT |
Number of registered new and relapsed TB cases with documented HIV status, during the reporting period |
2019 |
172 |
TB_STAT |
Total number of registered new and relapsed TB cases, during the reporting period |
2019 |
172 |
TB_STAT_den |
Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) |
2019 |
34 |
TB_STAT_den |
Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) |
2019 |
138 |
TX_CURR |
25-29, Female, Positive |
2019 |
6 |
TX_CURR |
25-29, Female, Positive |
2019 |
4 |
TX_CURR |
25-29, Male, Positive |
2019 |
21 |
TX_CURR |
25-29, Male, Positive |
2019 |
14 |
TX_CURR |
30-34, Female, Positive |
2019 |
16 |
TX_CURR |
30-34, Female, Positive |
2019 |
16 |
TX_CURR |
30-34, Male, Positive |
2019 |
46 |
TX_CURR |
30-34, Male, Positive |
2019 |
31 |
TX_CURR |
35-39, Female, Positive |
2019 |
18 |
TX_CURR |
35-39, Female, Positive |
2019 |
22 |
TX_CURR |
35-39, Male, Positive |
2019 |
52 |
TX_CURR |
35-39, Male, Positive |
2019 |
48 |
TX_CURR |
40-49, Female, Positive |
2019 |
12 |
TX_CURR |
40-49, Female, Positive |
2019 |
10 |
TX_CURR |
40-49, Male, Positive |
2019 |
34 |
TX_CURR |
40-49, Male, Positive |
2019 |
7 |
TX_CURR |
Number of adults and children receiving antiretroviral therapy (ART) |
2019 |
205 |
TX_CURR |
Number of adults and children receiving antiretroviral therapy (ART) |
2019 |
152 |
TX_NEW |
25-29, Female, Positive |
2019 |
3 |
TX_NEW |
25-29, Female, Positive |
2019 |
5 |
TX_NEW |
25-29, Male, Positive |
2019 |
5 |
TX_NEW |
25-29, Male, Positive |
2019 |
8 |
TX_NEW |
30-34, Female, Positive |
2019 |
3 |
TX_NEW |
30-34, Female, Positive |
2019 |
4 |
TX_NEW |
30-34, Male, Positive |
2019 |
6 |
TX_NEW |
30-34, Male, Positive |
2019 |
9 |
TX_NEW |
35-39, Female, Positive |
2019 |
1 |
TX_NEW |
35-39, Female, Positive |
2019 |
1 |
TX_NEW |
35-39, Male, Positive |
2019 |
3 |
TX_NEW |
35-39, Male, Positive |
2019 |
5 |
TX_NEW |
Number of adults and children newly enrolled on antiretroviral therapy (ART) |
2019 |
21 |
TX_NEW |
Number of adults and children newly enrolled on antiretroviral therapy (ART) |
2019 |
32 |
TX_PVLS |
Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months |
2019 |
205 |
TX_PVLS |
Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months |
2019 |
152 |
TX_PVLS_den |
Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine |
2019 |
52 |
TX_PVLS_den |
Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine |
2019 |
52 |
TX_PVLS_den |
Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine |
2019 |
153 |
TX_PVLS_den |
Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine |
2019 |
100 |
TX_PVLS_den |
Denominator: Indication: Routine |
2019 |
205 |
TX_PVLS_den |
Denominator: Indication: Routine |
2019 |
152 |